Fischer Medical Ventures Limited (FMVL), listed on the BSE (Scrip Code: 524743) and the NSE (Symbol: FISCHER), announced the appointment of Mr. Tay Chin Kwang as Group Director of Finance, Chairman Office, strengthening the Company’s leadership team as it advances its long-term strategy for growth, governance and international expansion.
Chin Kwang is a seasoned finance leader with more than two decades of experience across listed companies, high-growth ventures and advisory environments in Singapore and Southeast Asia. He brings extensive expertise in strategic finance, fundraising, investor relations, mergers and acquisitions, corporate restructuring, governance and finance transformation.
Throughout his career, Chin Kwang has worked closely with boards of directors, investors, executive leadership and key stakeholders, leading finance strategy, capital raising initiatives, regional operations and cross-border expansion. His experience includes serving as Chief Financial Officer of various companies listed in the stock exchange of Singapore, as well as advising businesses on fundraising, IPO readiness, strategic partnerships and restructuring. He has also supported fundraising initiatives for a China-based life sciences company focused on cancer treatment.
In his new role, Chin Kwang will work closely with the Chairman’s Office to strengthen the Group’s financial strategy, corporate governance, investor engagement and strategic growth initiatives while supporting Fischer Medical Ventures’ expanding presence in healthcare, life sciences and technology-driven businesses.
Mr. Ravindran Govindan, Chairman, Fischer Medical Ventures Limited, said:
“We are delighted to welcome Mr. Tay Chin Kwang to Fischer Medical Ventures Limited. His extensive experience in strategic finance, investor relations, fundraising and corporate governance will be invaluable as we continue to strengthen our business and pursue new growth opportunities. His leadership will further enhance our financial discipline, strategic execution and long-term value creation for all stakeholders.”
Mr. Tay Chin Kwang, Group Director of Finance, Chairman Office, Fischer Medical Ventures Limited said:
“I am honoured to join Fischer Medical Ventures Limited at an exciting stage of its growth journey. The Company has a clear vision to build a strong healthcare and life sciences platform, and I look forward to working closely with the Chairman, Board and management team to strengthen the Group’s financial strategy, support sustainable growth and create long-term value for shareholders while advancing its strategic objectives.”
The appointment reflects Fischer Medical Ventures’ continued commitment to strengthening its leadership team with experienced professionals who can support the Company’s long-term growth strategy, enhance corporate governance and drive sustainable value creation for shareholders.
++++++
About Fischer Medical Ventures Limited
Fischer Medical Ventures Limited (FMVL, the “Company”), Headquartered in Andhra Pradesh, with a facility at the Andhra Pradesh MedTech Zone (AMTZ), Visakhapatnam, its subsidiary Time Medical International Ventures (India) Private Limited (TMIVPL) is the first Indian company recognized by CDSCO for indigenously manufacturing MRI systems.
FMVL focuses on medical diagnostics, digital health, and AI-powered healthcare software. Its product range includes MRI systems (0.35T & 1.5T), preventive health kiosks, e-health access points (E-HAPs), AI-based software for cancer and TB screening, handheld X-ray devices, SpinCare technology, nutraceuticals from plant extracts, and contactless mental health screening. Upcoming products include oncology and CT scan solutions. FMVL aims to make healthcare accessible and affordable through innovation and data-driven solutions. Its 100% subsidiary FlynnCare Health Innovations Pvt. Ltd. provides digital platforms for community health screening and hospital connectivity.